Iol Chemicals Pharmaceuticals Ltd vs Sun Pharma Advanced Research Company Ltd Stock Comparison
Iol Chemicals Pharmaceuticals Ltd vs Sun Pharma Advanced Research Company Ltd Stock Comparison
Last Updated on: May 05, 2026
Key Highlights
The Latest Trading Price of IOL Chemicals & Pharmaceuticals Ltd is ₹ 94.66 as of 05 May 15:30
. The P/E Ratio of IOL Chemicals & Pharmaceuticals Ltd changed from 12.4 on March 2022 to 17.8 on March 2025 . This represents a CAGR of 9.46% over 4 yearsThe P/E Ratio of Sun Pharma Advanced Research Company Ltd changed from -14 on March 2025 to -14 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of IOL Chemicals & Pharmaceuticals Ltd changed from ₹ 2077 crore on March 2022 to ₹ 1796 crore on March 2025 . This represents a CAGR of -3.56% over 4 yearsThe Market Cap of Sun Pharma Advanced Research Company Ltd changed from ₹ 5823 crore on March 2023 to ₹ 4802 crore on March 2025 . This represents a CAGR of -6.22% over 3 years The revenue of IOL Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 585.68 crore as compare to the Sep '25 revenue of ₹ 574.41 crore. This represent the growth of 1.96% The revenue of Sun Pharma Advanced Research Company Ltd for the Dec '25 is ₹ 8.45 crore as compare to the Sep '25 revenue of ₹ 7.87 crore. This represent the growth of 7.37% The ebitda of IOL Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 51.36 crore as compare to the Sep '25 ebitda of ₹ 63.96 crore. This represent the decline of -19.7% The ebitda of Sun Pharma Advanced Research Company Ltd for the Dec '25 is ₹ -69 crore as compare to the Sep '25 ebitda of ₹ -65.71 crore. This represent the growth of 5.01% The net profit of IOL Chemicals & Pharmaceuticals Ltd changed from ₹ 29.97 crore to ₹ 20.58 crore over 7 quarters. This represents a CAGR of -19.33%
The net profit of Sun Pharma Advanced Research Company Ltd changed from ₹ -95.9 crore to ₹ -80.42 crore over 7 quarters. This represents a CAGR of -9.57%
The Dividend Payout of IOL Chemicals & Pharmaceuticals Ltd changed from 7.92 % on March 2021 to 23.25 % on March 2025 . This represents a CAGR of 24.03% over 5 yearsThe Dividend Payout of Sun Pharma Advanced Research Company Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About IOL Chemicals & Pharmaceuticals Ltd
IOL Chemicals and Pharmaceuticals Limited, incorporated in September, 1986 is a renowned company in the Active Pharmaceutical
Ingredient (API) and specialty chemicals sectors.
Its extensive expertise in both API and specialty chemicals strengthens the business model and opens doors to diversified growth opportunities.
Within the API segment, IOL develops and supplies a wide range of essential products utilized by pharmaceutical companies worldwide for the production of key medicines.
It serves as a global supplier of various APIs, including Ibuprofen, Metformin, Clopidogrel, Lamotrigine, Pantoprazole, and Fenofibrate, alongside other APIs, and maintains a significant presence in all major therapeutic categories.
In the Specialty Chemicals division, IOL manufactures Ethyl Acetate, Iso Butyl Benzene (IBB), Mono Chloro Acetic Acid (MCA), and Acetyl Chloride.
About Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems.
The Company works on innovation and new product development for global markets.
They undertake projects in research and technology for new chemical entities (NCE's) or new molecules, and novel drug delivery systems (NDDS).
Sun Pharmaceutical Advanced Research Company Limited was incorporated on March 1, 2006 as an innovative and development company.
It commenced operations on March 22, 2006.
As per Scheme of Arrangement, the entire business undertaking of the Innovative Research & Development including Novel Drug Delivery System (NDDS) Division of Sun Pharmaceuticals Industries' Research & Development Undertaking was transferred and vested into the Company effective from February 28, 2007.
FAQs for the comparison of IOL Chemicals & Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd
Which company has a larger market capitalization, IOL Chemicals & Pharmaceuticals Ltd or Sun Pharma Advanced Research Company Ltd?
Market cap of IOL Chemicals & Pharmaceuticals Ltd is 2,778 Cr while Market cap of Sun Pharma Advanced Research Company Ltd is 4,536 Cr
What are the key factors driving the stock performance of IOL Chemicals & Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd?
The stock performance of IOL Chemicals & Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for IOL Chemicals & Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd?
As of May 5, 2026, the IOL Chemicals & Pharmaceuticals Ltd stock price is INR ₹94.66. On the other hand, Sun Pharma Advanced Research Company Ltd stock price is INR ₹139.8.
How do dividend payouts of IOL Chemicals & Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd compare?
To compare the dividend payouts of IOL Chemicals & Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.